[Sinonasal extranodal natural killer/T-cell lymphoma: a case report and review of recent developments in the management].
Nasal extranodal natural killer/T-cell lymphoma, which is a highly aggressive disease, is more frequently seen in Asia than in Western countries. No consensus has been reached on the management of the disease and the survival depends on the stage of the disease. Localized NK/T-cell lymphoma often responds to radiotherapy well. However, patients with advanced disease or recurrence after chemoradiotherapy, similar to our patient, have a very poor prognosis. In this article, we present a 52-year-old male patient with early recurrence and who was refractory to chemotherapy. The management of the disease was reviewed in the light of the recent literature data.
Department of Radiation Oncology, Medical Faculty of İstanbul University, İstanbul, Turkey.
Rabia Nergiz
RN
Dağoğlu
Oner
O
Ozdemir
Arzu
A
Ergen
Fulya Yaman
FY
Ağaoğlu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059248:Chemoradiotherapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone